Although only two or three studies were performed for several biomarkers [PRX1, PRX2, PRX4, PRX6, and secretagogin], the results might be reliable, as their heterogeneity is lower than 33% and their SMD indicates a moderate to strong difference between T2D and controls. This evidence concerns the gene PRDX4 and type 2 diabetes mellitus.